The GNB5 Knockout HeLa Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal population of HeLa cells carrying targeted disruption of the GNB5 gene. This polyclonal knockout pool is generated to ablate GNB5 protein expression, providing a versatile loss-of-function model for investigating the roles of the G protein beta-5 subunit in a human epithelial cancer cell context. The product is supplied as a heterogeneous cell population, suitable for pooled assays and studies where clonal variation is not a primary concern.
HeLa cells are an immortalized human epithelial cell line originally derived from cervical adenocarcinoma. As a well-established cancer cell model, HeLa cells offer robust growth characteristics and are extensively employed in signal transduction research, drug discovery, and functional genomics. Their epithelial origin and ability to be easily manipulated make them a suitable host for generating knockout models to study G protein-coupled receptor (GPCR) signaling and cancer-related pathways. This cell line’s fast doubling time and amenability to transfection further support high-throughput experimental designs.
GNB5 encodes the beta-5 subunit of heterotrimeric G proteins, which assembles into complexes with regulator of G protein signaling (RGS) proteins such as RGS7, RGS6, and RGS9. Within the GPCR signaling cascade, GNB5-containing dimers mediate signal propagation downstream of receptor activation by ligands including lysophosphatidic acid and sphingosine-1-phosphate. These complexes modulate the activity of G protein alpha subunits and influence effectors such as PLC-beta and ion channels, thereby regulating second messenger systems including calcium and the PI3K/AKT pathway. Disruption of GNB5 in HeLa cells is expected to perturb GPCR-driven signaling networks by destabilizing RGS protein complexes and altering G protein deactivation kinetics.
In the HeLa cervical adenocarcinoma background, GNB5 knockout provides a powerful system to dissect the contribution of G beta-5?CRGS complexes to oncogenic signaling and cellular behaviors. Given that GPCRs and their downstream effectors are frequently implicated in cancer progression, this model enables investigation of how GNB5 loss influences proliferation, survival, and migration in an epithelial tumor context. Although GNB5 mutations are linked to neurodevelopmental disorders and intellectual disability, the HeLa model allows detailed biochemical and functional studies of GNB5-dependent signaling modules that are conserved across tissues, offering insights relevant to both cancer biology and rare neurological diseases.
Researchers can employ this polyclonal GNB5 knockout model to investigate GPCR signaling mechanisms, RGS protein complex formation, and G protein beta subunit function in non-neuronal cells. Typical readouts include western blotting to confirm GNB5 ablation, cAMP and calcium flux assays to assess GPCR responsiveness, and co-immunoprecipitation to examine RGS protein interactions. Transcriptomic analyses via RNA-seq, together with proliferation, apoptosis, and migration assays, further enable comprehensive functional characterization. This cell population is well suited for drug target validation studies focusing on G protein-mediated pathways. For further technical information, please contact Ascent Research.
